Global biopharmaceutical behemoth Pfizer Inc. (PFE) has delivered a better-than-anticipated second-quarter performance on both its top-line and bottom-line. Driven by the robust performance of Paxlovid and Comirnaty, revenue jumped 47% year-over-year to $27.7 billion. Earnings per share (EPS) at $2.04 comfortably beat the Street’s expectations of $1.72, registering a 92% year-over-year growth in the company’s bottom line. Additionally, the company also took its full-year 2022 guidance up a notch. It now expects revenue to be between $98 billion and $102 billion. Adjusted EPS is anticipated to be between $6.30 and $6.45.
https://www.tipranks.com/news/pfizer-posts-q2-beat-bottom-line-surges-92?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Pfizer Charts.